• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Substantiating the concerns about recombinant human activated protein C use in sepsis.

作者信息

Deans Katherine J, Minneci Peter C, Banks Steven M, Natanson Charles, Eichacker Peter Q

出版信息

Crit Care Med. 2004 Dec;32(12):2542-3. doi: 10.1097/01.ccm.0000148090.94378.6a.

DOI:10.1097/01.ccm.0000148090.94378.6a
PMID:15599164
Abstract
摘要

相似文献

1
Substantiating the concerns about recombinant human activated protein C use in sepsis.证实对重组人活化蛋白C用于脓毒症治疗的担忧。
Crit Care Med. 2004 Dec;32(12):2542-3. doi: 10.1097/01.ccm.0000148090.94378.6a.
2
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.重组人活化蛋白C用于脓毒症治疗：试验结果不一致、作用机制不明以及安全性问题导致了标签限制和开展IV期试验的必要性。
Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013.
3
Should we be using activated protein C to treat severe sepsis?我们应该使用活化蛋白C来治疗严重脓毒症吗？
Br J Hosp Med (Lond). 2009 Aug;70(8):484. doi: 10.12968/hmed.2009.70.8.43548.
4
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.重组人活化蛋白C美国试验（ENHANCE US）的扩展评估：一项关于重组人活化蛋白C（活性）用于严重脓毒症的单臂、3B期、多中心研究。
Chest. 2004 Jun;125(6):2206-16. doi: 10.1378/chest.125.6.2206.
5
The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.严重脓毒症综合征的流行病学及其重组人活化蛋白C治疗
Expert Opin Pharmacother. 2003 Oct;4(10):1789-99. doi: 10.1517/14656566.4.10.1789.
6
Assessing the use of activated protein C in the treatment of severe sepsis.评估活化蛋白C在严重脓毒症治疗中的应用。
N Engl J Med. 2002 Sep 26;347(13):1030-4. doi: 10.1056/NEJMsb021512.
7
Recombinant activated protein C in pediatric sepsis.重组活化蛋白C用于儿童脓毒症
Pediatr Infect Dis J. 2003 Aug;22(8):743-5. doi: 10.1097/01.inf.0000079362.16086.0c.
8
[Exogenous activated protein C in severe sepsis].[严重脓毒症中外源性活化蛋白C]
Anesteziol Reanimatol. 2005 May-Jun(3):42-5.
9
Activated protein C for the treatment of severe sepsis.活化蛋白C治疗严重脓毒症
Clin Microbiol Infect. 2009 Apr;15(4):319-24. doi: 10.1111/j.1469-0691.2009.02751.x.
10
[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].[重组活化蛋白C：从证据到临床实践。活化蛋白C用于治疗严重脓毒症的临床实践指南]
Ugeskr Laeger. 2004 Mar 8;166(11):997-1002.

引用本文的文献

1
Recombinant human activated protein C for severe sepsis in neonates.重组人活化蛋白C用于新生儿严重脓毒症
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD005385. doi: 10.1002/14651858.CD005385.pub3.
2
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.对脓毒症中活化蛋白C给药潜在益处和风险的深入认识：临床前和临床研究综述
Biologics. 2009;3:391-406. doi: 10.2147/btt.2009.3547. Epub 2009 Sep 15.
3
[Endogenous anticoagulant therapy for sepsis. Success and failure].
[脓毒症的内源性抗凝治疗。成功与失败]
Internist (Berl). 2007 May;48(5):537-42, 544. doi: 10.1007/s00108-007-1840-y.
4
Increasing evidence that the risks of rhAPC may outweigh its benefits.越来越多的证据表明，重组人活化蛋白C（rhAPC）的风险可能超过其益处。
Intensive Care Med. 2007 Mar;33(3):396-9. doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.
5
Activated protein C: do more survive?活化蛋白C：更多患者能存活吗？
Intensive Care Med. 2005 Dec;31(12):1624-6. doi: 10.1007/s00134-005-2829-4. Epub 2005 Oct 15.